Harvard's Wyss Institute licenses infant health-promoting technology to Prapela

August 22, 2018

Wyss Institute

The startup company will initially focus on infants suffering from neonatal abstinence syndrome.

BOSTON, Aug. 22, 2018 /PRNewswire/ -- Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Prapela Inc. announced that the Institute's clinically validated Stochastic Vibro-tactile Stimulation (SVS) technology will be commercialized by the startup to develop a range of devices designed to improve infant health. The announcement follows a licensing agreement between Harvard's Office of Technology Development (OTD) and Prapela.

Some infants are born with, or develop, instabilities in their heart and lung (cardiorespiratory) function. Newborn infants most frequently affected include those suffering from neonatal abstinence syndrome (NAS), which is caused by withdrawal from drugs like opioids that their mothers consumed during their pregnancies.

Prapela will use the technology developed at the Wyss Institute to design an inexpensive, SVS hospital bassinet pad and a next-generation, 'baby box'. The original baby box was developed in Finland to provide all infants, regardless of their families' social background, with a safe sleeping environment until they can transition to a crib.

Read the full article 

Stay In Touch